• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

    8.485 +0.045 (+0.53%)
    Streaming Delayed Price Updated: 10:16 AM EDT, Oct 21, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 338,623
    Open 8.400
    Bid (Size) 8.480 (5)
    Ask (Size) 8.490 (7)
    Prev. Close 8.440
    Today's Range 8.390 - 8.570
    52wk Range 5.510 - 12.65
    Shares Outstanding 266,555,274
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
     
    Via Benzinga
    New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
    Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® 
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -8.9%
    -8.9%
    1 Month
    -1.0%
    -1.0%
    3 Month
    +40.2%
    +40.2%
    6 Month
    +26.5%
    +26.5%
    1 Year
    -29.4%
    -29.4%

    More News

    Read More
    Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For July 31, 2025
    Via Benzinga
    Earnings Scheduled For May 1, 2025
    Via Benzinga
    Amicus Therapeutics Earnings Preview
    Via Benzinga
    Earnings Scheduled For February 19, 2025
    Via Benzinga
    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
    Via Investor Brand Network
    Topics Government
    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
    Via FinancialNewsMedia
    Topics Government
    Amicus (FOLD) Q2 Revenue Jumps 22%
    Via The Motley Fool
    Topics Intellectual Property
    Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading
    Via Chartmill
    Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
    From Amicus Therapeutics, Inc.; Dimerix Limited
    Via GlobeNewswire
    Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire
    Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
    From Amicus Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Amicus Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Amicus Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Amicus Therapeutics, Inc. - Common Stock trade on?
    Amicus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Amicus Therapeutics, Inc. - Common Stock?
    The ticker symbol for Amicus Therapeutics, Inc. - Common Stock is FOLD on the Nasdaq Stock Market
    What is the current price of Amicus Therapeutics, Inc. - Common Stock?
    The current price of Amicus Therapeutics, Inc. - Common Stock is 8.485
    When was Amicus Therapeutics, Inc. - Common Stock last traded?
    The last trade of Amicus Therapeutics, Inc. - Common Stock was at 10/21/25 10:16 AM ET
    What is the market capitalization of Amicus Therapeutics, Inc. - Common Stock?
    The market capitalization of Amicus Therapeutics, Inc. - Common Stock is 2.26B
    How many shares of Amicus Therapeutics, Inc. - Common Stock are outstanding?
    Amicus Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.